What if Section 232 pharma tariffs hit Irish/Swiss-made US drug imports?
A 25% national-security tariff on imported finished drugs and APIs raises COGS for Pfizer, Merck and Novartis, squeezing margins and accelerating costly US plant reshoring.
Every number ships with its receipt — the odds, the range, the precedents, and a public grade at Reality Check. The statistical machinery that produces it is proprietary.
The butterfly cascade
How this trigger trickles across markets, left → right — the root shock, its first‑order moves, then the ripple effects. Drag any node; tap a market for its real price history.
Resolution timeline — how this probability is moving
Our model's odds (electric blue) over time vs the market's (Polymarket, amber), from the past toward the 6–18 months horizon. Each dot is a real macro event that nudged the probability — green pushed it up, red pushed it down. Tap a dot for the source. Loading the probability audit trail…
What it would mean
If this plays out, it is a risk-off shock. A 25% national-security tariff on imported finished drugs and APIs raises COGS for Pfizer, Merck and Novartis, squeezing margins and accelerating costly US plant reshoring. The trigger decomposes into signed root‑shocks — Biotech breakthrough ▼ · Industrial demand ▲ · Risk appetite ▼ — which propagate through our causal graph to the markets below.